Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442870 | 1.00 | TUBB4A (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL153586 | 1.00 | TUBB4A (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29442809 | 0.94 | TUBB4A (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11981 | 0.94 | TUBB4A (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL63612 | 0.92 | TUBB4A (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Fluoride SCHEMBL542370 | 0.92 | TUBB4A (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL563962 | 0.87 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Phosphoric Acid SCHEMBL635361 | 0.87 | FAAH (0.35) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Phosphoric Acid SCHEMBL635362 | 0.86 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4438753 | 0.86 | TUBB4A (0.33) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363878-B1 | PROCESS FOR PREPARING SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES | YONSUNG FINE CHEMICAL CO LTD (KR) | 2007-01-17 | — | — | EP | claimed |
| EP-1363878-A4 | PROCESS FOR PREPARING SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES | YONSUNG FINE CHEMICAL CO LTD (KR) | 2005-12-21 | — | — | EP | claimed |
| US-6914159-B1 | Which have excellent therapeutic effects against hypertension, congestive heart failure, angina pectoris or prostatic hypertrophy higher yield; isolation step i.e. chromatography is not needed | YONSUNG FINE CHEMICAL CO., LTD. (KR) | 2005-07-05 | — | — | US | claimed |
| EP-1363878-A1 | PROCESS FOR PREPARING SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES | Yonsung Fine Chemical Co. Ltd (KR) | 2003-11-26 | — | — | EP | claimed |
| WO-2002068382-A1 | PROCESS FOR PREPARING SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES | YONSUNG FINE CHEMICAL CO. LTD. (KR) | 2002-09-06 | — | — | WO | claimed |
| JP-9208697-A | — | — | None | — | — | JP | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-3690038-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-3502693-A1 | CELL TRACKING REAGENTS AND THEIR METHODS OF USE | Life Technologies Corporation (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20090292108-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | ROCHE PALO ALTO LLC | 2009-11-26 | — | — | US | disclosed |
| US-20090130214-A1 | Gemcitabine derivatives nanoparticles | Universite Paris-Saclay (FR) | 2009-05-21 | — | — | US | disclosed |
| EP-2055711-A1 | Use of squalenic acid for the formulation of an active principle in nanoparticle state | Centre National de la Recherche Scientifique (FR) | 2009-05-06 | — | — | EP | disclosed |
| EP-1925624-A1 | Use of squalenic acid for the formulation of an active principle in nanoparticle state | Centre National de la Recherche Scientifique (FR) | 2008-05-28 | — | — | EP | disclosed |
| EP-1761551-A1 | GEMCITABINE DERIVATIVES NANOPARTICLES | The Centre National de la Recherche Scientifique (FR) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006090029-A1 | GEMCITABINE DERIVATIVES NANOPARTICLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-31 | — | — | WO | disclosed |
| US-6914159-B1 | Which have excellent therapeutic effects against hypertension, congestive heart failure, angina pectoris or prostatic hypertrophy higher yield; isolation step i.e. chromatography is not needed | YONSUNG FINE CHEMICAL CO., LTD. (KR) | 2005-07-05 | — | — | US | disclosed |
| JP-H09208697-A | PRODUCTION OF POLYMERIC COMPOUND | HITACHI CHEM CO LTD | 1997-08-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | TUBB4A 346/4885TUBB 670/4885TUBA3C 394/4885 |
| US-20090130214-A1 | Gemcitabine derivatives nanoparticles | KRAS, H1-3, MCL1 | TUBB4A 218/4885TUBB 119/4885TUBA3C 54/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | TUBB4A 1088/4885TUBB 1572/4885TUBA3C 1334/4885 |
| US-20090292108-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | IAPP, GLP1R, GIPR | TUBB4A 4499/4885TUBB 4246/4885TUBA3C 3611/4885 |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | TUBB4A 346/4885TUBB 670/4885TUBA3C 394/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | TUBB4A 249/4885TUBB 554/4885TUBA3C 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.